TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05194163
Drug: MW150
Normalized name: Minocycline hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral-delivered capsule of study drug
Study: NCT05194163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral delivered capsule matched to study drug capsule
Study: NCT05625347
Drug: single dose (162 mg) of non-enteric-coated chewable aspirin tablets
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: orally administered
Study: NCT06183242
Drug: Remaxa, enteric-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: enteric-coated tablets
Study: NCT06183242
Drug: Remaxol
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for infusions
Study: NCT06183242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: enteric-coated tablets
Study: NCT05861765
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: After inserting the radial artery sheath, slowly inject 10ml normal saline(0.9%) through the artery sheath, then continuously drip normal saline(0.9%, 500ml, 4ml/min) through the artery sheath during the operation.
Study: NCT06155110
Drug: cardiomyopeptidin
Approvals — FDA: no, EMA: no, PMDA: no
Description: cardiomyopeptidin intervention group will accept cardiomyopeptidin (Dalian Zhenao Pharmaceutical Co., Ltd., approval number: National Drug Approval No. H20052173, specification: 20 mg/tube) 3 mg/(kg·d)；
Study: NCT05399368
Drug: RPT193
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
Study: NCT04825860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
Study: NCT06333977
Drug: LC542019
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose, once daily
Study: NCT06333977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT05974683
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue use of current basic maintenance treatment of IgG4-RD plus placebo, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
Study: NCT05476510
Drug: Postoperative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
Study: NCT05638347
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration
Study: NCT06520891
Drug: Statin and SGLT2i
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin as atrovastatin SGLT2i as dapagliflozin
Study: NCT05393089
Drug: AGN-190584
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drops
Study: NCT05393089
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drops
Study: NCT06485336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet will be taken once daily for 84 days.
Study: NCT05245591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 100 mg three times daily (tid) for 0-8 weeks Placebo 100 mg twice daily (bid) for 9-16 weeks
Study: NCT05205109
Drug: KEYTRUDA ®( Pembrolizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part I: After 2 cycles of ATG-037 monotherapy, eligible participants will receive ATG-037 combination therapy with Keytruda ®(Pembrolizumab) 200mg/Q3W fixed dose for up to 35 administrations (approximately 2 years).~Part II: Keytruda ®(Pembrolizumab) will be administered from C1.
Study: NCT05203705
Drug: SHR2285 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2285 tablet; dose 1, for 12 days
Study: NCT05203705
Drug: SHR2285 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2285 tablet; dose 4, for 12 days
Study: NCT04831047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of placebo (balanced saline solution) will be applied to the ocular surface of each eye.
Study: NCT05857579
Drug: Home-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based therapy was based on Therapearl eye mask warming compress (Bausch \& Lomb, Madrid, Spain) twice a day and Eyestil synfo eyedrops (Sifi Iberica SL, Madrid, Spain) 4 times a day during the study
Study: NCT04867785
Drug: LY3437943
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04867785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05789576
Drug: VTAMA (tapinarof) cream, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTAMA (tapinarof) cream, 1% applied topically once daily
Study: NCT05678283
Drug: [14C]CC-90010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06009042
Drug: IVIG 20g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of IVIG(intravenous immunoglobulin) is 20g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.
Study: NCT06009042
Drug: IVIG 10g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of IVIG(intravenous immunoglobulin) is 10g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.
Study: NCT04312932
Drug: LCPUFA Oil Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
Study: NCT05631041
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants in silymarin group will receive silymarin 140 mg once daily.
Study: NCT06359600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05653271
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting agent
Study: NCT04744181
Drug: B vitamin
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of a single dose of B vitamin in those patietns who fulfill the inclusion criteria
Study: NCT04744181
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of a single dose of folic acid in those patietns who fulfill the inclusion criteria
Study: NCT05979428
Drug: NNC0491-6075
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
Study: NCT05979428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
Study: NCT06258213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05656443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04994704
Drug: Propfol group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.
Study: NCT06514976
Drug: Cytoflavin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin solution for infusions. 20-40 ml/day (10 ml with the interval of 8-12 hours for 10 days; the single dose is increased up to 20 ml in case of the severe form of the disease) by intravenous drop infusion in dilution per 100-200 ml of 0.9% sodium chloride solution for 10 days; rate of administration: 3-4 ml/min
Study: NCT04848662
Drug: BDA MDI (PT027) 160/180 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 μg per puff. Two puffs to administer 160/180 μg dose.
Study: NCT04848662
Drug: Pulmicort Respules 0.5 MG/ML Inhalation Suspension
Normalized name: Pulmicort Respules 0.5 MG/ML Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide.
Study: NCT04796675
Drug: Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
Study: NCT05777109
Drug: Xgeva®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
Study: NCT06151210
Drug: Stillen® Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets/day
Study: NCT06151210
Drug: DA-5219 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet/day
Study: NCT06151210
Drug: Stillen® Tab Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets/day
Study: NCT04930328
Drug: Oxbryta® (voxelotor) 500-mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will have received treatment with Oxbryta as prescribed by their physician at the approved dose per local prescribing information, as part of their usual care.
Study: NCT05736419
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered Post-Transplant
Study: NCT06085053
Drug: TQA3038 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQA3038 is an injection.
Study: NCT06085053
Drug: TQA3038 injection matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection contains no active substance.
Study: NCT00513201
Drug: regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05478382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are given 0 to 3 capsules per administration according to their allocated group.
Study: NCT05739136
Drug: Relugolix + Estradiol + Norethindrone Acetate
Normalized name: estradiol / norethindrone / relugolix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix combination therapy (relugolix 40 mg; estradiol 1 mg; norethindrone 0.5 mg)
Study: NCT05372887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
Study: NCT06175117
Drug: compound E Jiao Jiang(cEJJ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: compound E Jiao Jiang(cEJJ)：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.
Study: NCT06175117
Drug: compound E Jiao Jiang(cEJJ) placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: compound E Jiao Jiang(cEJJ) placebo：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.~ferrous succinate tablet：1 tablet at a time, 2 times a day, should be taken in the morning, after dinner or during meals.
Study: NCT05317507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05280197
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block using normal saline
Study: NCT05952947
Drug: Fludarabine + Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days
Study: NCT05321706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized in a 1:1 fashion to receive a matching placebo once daily for one year.
Study: NCT06121518
Drug: D064 and D702, QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Group Subjects assigned to this group are treated with D064, D702
Study: NCT06121518
Drug: D064 and Placebo of D702, QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator Group Subjects assigned to this group are treated with D064, placebo of D702
Study: NCT06121518
Drug: Placebo of D064 and D702, QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator Group Subjects assigned to this group are treated with D702, placebo of D064
Study: NCT04781647
Drug: ABI-H0731
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ABI-H0731 300 mg tablets orally once daily
Study: NCT05196971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 sprays of placebo self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
Study: NCT05284955
Drug: Standard heart failure medical therapy
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heart failure medical therapy as recommended by guidelines.
Study: NCT04399343
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
Study: NCT04865042
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive in addition to the usual analgesic treatment, the Placebo During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be made.~The patient will have to take the treatment as follows:~* Day 1 (1st day of hospitalization): 1 capsule/day~* Day 2: 2 capsules/day~* Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed.
Study: NCT06176820
Drug: Vaginal Gel
Normalized name: VAGINAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1 will apply 2.5 gram of VHAL gel intravaginally using vaginal applicator 2 times per week for 3 months
Study: NCT06176820
Drug: Vaginal lubricant
Normalized name: Film, Multi Ingredient Vaginal Film [VCF VAGINAL LUBRICANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 2 will apply 2.5 gram of vaginal lubricant intravaginally using vaginal applicator 2 times per week for 3 months
Study: NCT06139991
Drug: Treatment B (BDA MDI HFA)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized participants will receive Treatment B (BDA MDI HFA) on Day 1 under fasted condition.
Study: NCT05614518
Drug: Technetium[99mTc] Methylenediphosphonate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject was given 10-25 mCi intravenously. Images were collected 3-6 hours after injection.
Study: NCT05879237
Drug: Helicobacter pylori triple therapy
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy which is: amoxcillin on 50 mg/kg/day for 2 weeks, Clarithromycin 20mg/kg/day for 2 weeks and proton pump inhibitor~3.ppi 1mg/kg/day for 1month
Study: NCT04954326
Drug: Lyophilized S95014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol.
Study: NCT05306249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the MCT oil placebo without CBD until the end of week 12.
Study: NCT06156059
Drug: Oral Bedtime Melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral suspension or capsule given at bedtime
Study: NCT06156059
Drug: Placebo suspension or capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indistinguishable suspension or capsule
Study: NCT05771584
Drug: AST-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg
Study: NCT05011916
Drug: KDR2-2 suspension eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were instructed to instill one drop four times per day in the study eye for 6 weeks.
Study: NCT06486337
Drug: CMOP±R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 4 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1, every 4 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 2-3 mg/m2 on day 1), every 4 weeks; Drug: Prednisone Prednisone (100 mg) will be taken orally from day 1-5(Or equivalent dose of dexamethasone at 15mg), every 4 weeks; Drug: Rituximab Rituximab (375mg/m\^2) on day 0, every 4 weeks, only with CD20-positive lymphomas are evaluated by the investigator.
Study: NCT04908345
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Used at induction and during surgery
Study: NCT05828836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once daily
Study: NCT04976647
Drug: HLX10+chemo
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
Study: NCT04976647
Drug: HLX10+HLX07+chemo
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 1500mg IV q3w; HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
Study: NCT04393311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ulinastatin administered via IV infusion
Study: NCT04829123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by subcutaneous injection in the abdomen
Study: NCT03417921
Drug: ABTL0812
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABTL0812 in combination with gemcitabine and nab-paclitaxel
Study: NCT06489093
Drug: NSF
Normalized name: Transferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of NSF using a microapplicator on the carious lesion for 1 minute. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
Study: NCT06489093
Drug: SDF+KI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of 38% silver diamine fluoride (Riva star 38%, SDI) using a microapplicator on the carious lesion. Immediately afterwards, potassium iodide is applied as a reducing agent. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
Study: NCT00793247
Drug: PRU-PLA-PRU-PLA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00793247
Drug: PLA-PRU-PLA-PRU
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00793247
Drug: PLA-PRU-PRU-PLA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00793247
Drug: PRU-PLA-PLA-PRU
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04103554
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care used for treating BP
Study: NCT05088967
Drug: IBI110
Approvals — FDA: no, EMA: no, PMDA: no
Description: R2PD d1 IV every 3 weeks
Study: NCT05570305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo.
Study: NCT06342336
Drug: HS-IT101 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive transfer of 5x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
Study: NCT05143164
Drug: Gentamicin Sulfate, Topical
Normalized name: Gentamicin Sulfate, Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of gentamicin to exit site daily
Study: NCT06035081
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see arm description
Study: NCT05664789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT04837001
Drug: FDY-5301
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDY-5301 will be administered as a single IV bolus injection.
Study: NCT04702516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
Study: NCT06173011
Drug: QL2107
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
Study: NCT06173011
Drug: Keytruda®(china)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
Study: NCT06173011
Drug: Keytruda®(US)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
Study: NCT06146777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05570812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (4-week ramp, 4-week steady dosing)
Study: NCT05492812
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin
Study: NCT04553263
Drug: Contrave 8Mg-90Mg Extended-Release Tablet
Normalized name: Contrave 8mg-90mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone HCl/Bupropion HCl is an FDA-approved weight-loss medication with efficacy via the mesolimbic dopamine system to reduce hunger and help control cravings.
Study: NCT01539174
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01539174
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03826524
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine 1mg 1:10000 (10cc) per dose
Study: NCT00417053
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00417053
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no